izpis_h1_title_alt

Treatment of canine cognitive dysfunction with novel butyrylcholinesterase inhibitor
Zakošek, Maja (Avtor), Prpar Mihevc, Sonja (Avtor), Štrbenc, Malan (Avtor), Košak, Urban (Avtor), German Ilić, Ilija (Avtor), Trontelj, Jurij (Avtor), Žakelj, Simon (Avtor), Gobec, Stanislav (Avtor), Pavlin, Darja (Avtor), Majdič, Gregor (Avtor)

.pdfPDF - Predstavitvena datoteka, prenos (1,34 MB)
MD5: 2A7E6FFD649C1E4BB4A045BC8C9556C4
Opis: Open access
URLURL - Izvorni URL, za dostop obiščite https://www.nature.com/articles/s41598-021-97404-2 Povezava se odpre v novem oknu

Izvleček
Canine cognitive dysfunction (CCD) is common in aged dogs and has many similarities with Alzheimer’s disease. Unfortunately, like Alzheimer’s disease, CCD cannot be cured. In the present study, we treated dogs with CCD with our newly developed and characterized butyrylcholinesterase inhibitor (BChEi). Seventeen dogs were randomized into two groups (treated with BChEi and untreated) and followed for 6 months at regular check-ups. The dogs’ cognitive status was determined by a Canine Dementia Scale (CADES) questionnaire and two cognitive tests. In dogs with moderate cognitive impairment, treatment caused significant improvement in the clinical rating of cognitive abilities and the performance-based tests of cognitive functioning when compared to the untreated group (p < 0.001). Dogs treated with BChEi showed markedly improved cognitive function with enhanced quality of life. No side effects were observed in the treated dogs with moderate cognitive impairment. According to the results of this preliminary study, there is an indication that novel BChEi may be a promising drug for the treatment of CCD in dogs and may be an interesting candidate for the treatment of Alzheimer's disease in humans. However, further clinical studies are needed to confirm this.

Jezik:Angleški jezik
Ključne besede:Alzheimer’s disease, butyrylcholinesterase, butyrylcholinesterase inhibitor, canine cognitive dysfunction, canine dementia scale, dogs
Vrsta gradiva:Članek v reviji (dk_c)
Tipologija:1.01 - Izvirni znanstveni članek
Organizacija:VF - Veterinarska fakulteta
FFA - Fakulteta za farmacijo
Leto izida:2021
Poslano v recenzijo:15.12.2020
Datum sprejetja članka:17.08.2021
Datum objave članka:13.09.2021
Št. strani:10 str.
Številčenje:Vol. 11, art. 18098
UDK:636.7.09:616.892
ISSN pri članku:2045-2322
DOI:10.1038/s41598-021-97404-2 Povezava se odpre v novem oknu
COBISS.SI-ID:77000195 Povezava se odpre v novem oknu
Število ogledov:72
Število prenosov:21
Metapodatki:XML RDF-CHPDL DC-XML DC-RDF
 
Skupna ocena:(0 glasov)
Vaša ocena:Ocenjevanje je dovoljeno samo prijavljenim uporabnikom.
:
Objavi na:AddThis
AddThis uporablja piškotke, za katere potrebujemo vaše privoljenje.
Uredi privoljenje...

Gradivo je del revije

Naslov:Scientific reports
Skrajšan naslov:Sci. rep.
Založnik:Nature Publishing Group
ISSN:2045-2322
COBISS.SI-ID:18727432 Povezava se odpre v novem oknu

Gradivo je financirano iz projekta

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Številka projekta:P4-0053
Naslov:Endokrini, imunski in encimski odzivi pri zdravih in bolnih živalih

Financer:ARRS - Agencija za raziskovalno dejavnost Republike Slovenije (ARRS)
Številka projekta:P1-0208
Naslov:Farmacevtska kemija: načrtovanje, sinteza in vrednotenje učinkovin

Financer:EC - European Commission
Naslov:European Regional Development Fund
Akronim:Sonja Perpar Mihevc

Licence

Licenca:CC BY 4.0, Creative Commons Priznanje avtorstva 4.0 Mednarodna
Povezava:http://creativecommons.org/licenses/by/4.0/deed.sl
Opis:To je standardna licenca Creative Commons, ki daje uporabnikom največ možnosti za nadaljnjo uporabo dela, pri čemer morajo navesti avtorja.
Začetek licenciranja:13.09.2021

Podobna dela

Podobna dela v RUL:
Podobna dela v drugih slovenskih zbirkah:

Komentarji

Dodaj komentar

Za komentiranje se morate prijaviti.

Komentarji (0)
0 - 0 / 0
 
Ni komentarjev!

Nazaj